Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study - Poll - MDSpire

Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study

  • By

  • Martina Galasso

  • Ludovica Verde

  • Renato Patrone

  • Giovanni Ragozzino

  • Giuseppe Annunziata

  • Annamaria Colao

  • Luigi Barrea

  • Giovanna Muscogiuri

  • July 6, 2026

  • 0 min

Share

Original Source(s)

Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study

  • by Martina Galasso, Ludovica Verde, Renato Patrone, Giovanni Ragozzino, Giuseppe Annunziata, Annamaria Colao, Luigi Barrea, Giovanna Muscogiuri

  • July 6, 2026

Related Content

Beyond the tumor: the role of the gut microbiome in triple-negative breast cancer

The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis

Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications